COVID-19 Vaccine Covax-19

**Semantic type:** Immunologic Factor|Pharmacologic Substance|Virus

**Definition:** A coronavirus vaccine composed of a recombinant form of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein (SP) combined with a proprietary polysaccharide-based vaccine adjuvant, Advax-CpG55.2, with potential immunomodulating and anti-COVID-19 activities. Upon administration of Covax-19, the SARS-CoV-2 SP activates the immune system to produce anti-SARS-CoV-2 SP antibodies and T-cell responses against SARS-CoV-2 SP. The antibodies recognize the SP and kill SARS-CoV-2. This prevents SARS-CoV-2 infection. SP, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus. The proprietary adjuvant strongly stimulates both T-cell and antibody immune responses when combined with the recombinant SARS-CoV-2 SP.

**Synonyms:** - Covax-19 - SARS-CoV-2 Spike Protein Plus Adjuvant Advax-CpG55.2